Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study

Authors: Javier Ordás, Yolanda Millán, Rafaela Dios, Carlos Reymundo, Juana Martín de las Mulas

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

Feline mammary carcinoma has been proposed as a natural model of highly aggressive, hormone-independent human breast cancer. To further explore the utility of the model by adding new similarities between the two diseases, we have analyzed the oncogene HER-2 status at both the protein and the gene levels.

Methods

Formalin-fixed, paraffin-embedded tissue samples from 30 invasive carcinomas, 7 benign lesions and two normal mammary glands were analyzed. Tumour features with prognostic value were recorded. The expression of protein HER-2 was analyzed by immunohistochemistry and the number of gene copies by means of DNA chromogenic in situ hybridization.

Results

Immunohistochemical HER-2 protein overexpression was found in 40% of feline mammary carcinomas, a percentage higher to that observed in human breast carcinoma. As in women, feline tumours with HER-2 protein overexpression had pathological features of high malignancy. However, amplification of HER-2 was detected in 16% of carcinomas with protein overexpression, a percentage much lower than that observed in their human counterpart.

Conclusion

Feline mammary carcinoma would be a suitable natural model of that subset of human breast carcinomas with HER-2 protein overexpression without gene amplification.
Appendix
Available only for authorised users
Literature
1.
Siegel PM, Dankort DL, Hardy WR, Muller WJ: Novel activating mutations in the neu proto – oncogene involved in induction of mammary tumors. Mol Cell Biol. 1994, 14: 7068-7077.CrossRefPubMedPubMedCentral
2.
Sahin AA: Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol. 2000, 7: 158-166.CrossRefPubMed
3.
Ross JS, Fletcher JA, Bloom KJ, Linnette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004, 3: 379-398. 10.1074/mcp.R400001-MCP200.CrossRefPubMed
4.
Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Paccart MJ, Isola J: Chromogenic in Situ Hybridization. A practical alternative for fluorescence in Situ Hybridization to detect HER-2/neu oncogene amplification in Archival Breast Cancer Samples. Am J Pathol. 2000, 157: 1467-1472.CrossRefPubMedPubMedCentral
5.
Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JMS: Interlaboratory comparison of HER-2 oncogene amplification by chromogenic and fluorescence in situ hybridization. Clin Cancer Res. 2004, 10: 4793-4798. 10.1158/1078-0432.CCR-0428-03.CrossRefPubMed
6.
7.
Frese K: Comparative pathology of mammary tumors of domestic animals. Pathology of Neoplastic and Endocrine induced diseases of the breast. Edited by: Bäsler R, Hübner K. 1986, Stuttgart: Gustav Fischer Verlag, 44-61.
8.
Rutteman GR, Withrow SJ, MacEwen EG: Tumors of the mammary gland. Small Animal Clinical Oncology. Edited by: Withrow SJ, MacEwen BR. 2001, Philadelphia: W.B. Saunders Company, 455-477.
9.
Millanta F, Calandrella M, Citi S, Della Santa D, Poli A: Overexpression of HER-2 in feline invasive mammary carcinomas: An immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol. 2005, 42: 30-34. 10.1354/vp.42-1-30.CrossRefPubMed
10.
Winston J, Craft DM, Scase TJ, Bergman PJ: Immunohistochemical detection of HER-2/nu expression in spontaneous feline mammary tumours. VCO. 2005, 3: 8-15.
11.
De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo F: Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005, 65: 907-912.PubMed
12.
Ahern TE, Bird RC, Bird AE, Wolfe LG: Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res. 1996, 57: 693-696.PubMed
13.
Rungsipipat A, Tateyama S, Yamaguchi R, Uchida K, Miyoshi N, Hayashi T: Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci. 1999, 61: 27-32. 10.1292/jvms.61.27.CrossRefPubMed
14.
Martín de las Mulas J, Ordás J, Millán Y, Fernández-Soria V, Ramón y, Cajal S: Oncogene HER-2 in canine mammary gland carcinomas: An immunohistochemical and chromogenic in situ hybridization study. Breast. 2003, 80: 363-367.
15.
Dutra AP, Granja NV, Schmitt FC, Cassali GD: c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res. 2005, 37: 1673-1681.
16.
Kott C, Matz-Rensing K, Kaup FJ: Hercep test applied in mammary tumors in female dogs. Kleintierpraxis. 2005, 50: 221-227.
17.
Misdorp W, Else RW, Hellmen E, Lipscomb TP: Histological classification of the mammary tumors of the dog and the cat. Second series. 1999, Washington, DC: AFIP, VII:
18.
Castagnaro M, Casalone C, Ru G, Nervi GC, Bozzeta E, Caramelli M: Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. J Comp Pathol. 1998, 119: 263-275. 10.1016/S0021-9975(98)80049-2.CrossRefPubMed
19.
Martín de las Mulas J, van Niel M, Millán Y, Blakenstein MA, van Mil F, Misdorp W: Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay. Domes Anim Endocrinol. 2000, 18: 111-125. 10.1016/S0739-7240(99)00067-3.CrossRef
20.
Martín de las Mulas J, van Niel M, Millán Y, Blankenstein MA, Van Mil F, Misdorp W: Progesterone receptors in normal, dysplastic and tumorous feline mammary glands. Comparison with oestrogen receptors status. Res Vet Sci. 2002, 72: 153-161. 10.1053/rvsc.2001.0542.CrossRefPubMed
21.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.CrossRefPubMed
Metadata
Title
Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study
Authors
Javier Ordás
Yolanda Millán
Rafaela Dios
Carlos Reymundo
Juana Martín de las Mulas
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-179

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Research article

Factors associated with quality of life of outpatients with breast cancer and gynecologic cancers and their family caregivers: a controlled study

Research article

P-LAP/IRAP-induced cell proliferation and glucose uptake in endometrial carcinoma cells via insulin receptor signaling

Research article

18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high

Research article

The isothiocyanate class of bioactive nutrients covalently inhibit the MEKK1 protein kinase

Research article

Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model

Research article

HIF2α reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits